Andrew R. Branagan, Matthew Lei, Carolyn Tracey, Noopur S. Raje
{"title":"多发性骨髓瘤临床试验的最新进展和基本原理","authors":"Andrew R. Branagan, Matthew Lei, Carolyn Tracey, Noopur S. Raje","doi":"10.1002/acg2.59","DOIUrl":null,"url":null,"abstract":"<p>Significant progress has been made toward the development of effective therapies for multiple myeloma. Current treatment strategies include combinations of several different approved medication classes, including alkylating agents, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors, and monoclonal antibodies. In this review, we highlight currently active clinical trials for patients with multiple myeloma. Additionally, we describe emerging strategies in the design of future trials, which will include new combinations of available therapies, targeted therapies, immune-based therapies such as chimeric antigen receptors T-cells (CAR-Ts), and drugs with novel mechanisms of action.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.59","citationCount":"0","resultStr":"{\"title\":\"Updates and rationale of clinical trials in multiple myeloma\",\"authors\":\"Andrew R. Branagan, Matthew Lei, Carolyn Tracey, Noopur S. Raje\",\"doi\":\"10.1002/acg2.59\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Significant progress has been made toward the development of effective therapies for multiple myeloma. Current treatment strategies include combinations of several different approved medication classes, including alkylating agents, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors, and monoclonal antibodies. In this review, we highlight currently active clinical trials for patients with multiple myeloma. Additionally, we describe emerging strategies in the design of future trials, which will include new combinations of available therapies, targeted therapies, immune-based therapies such as chimeric antigen receptors T-cells (CAR-Ts), and drugs with novel mechanisms of action.</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.59\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.59\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.59","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Updates and rationale of clinical trials in multiple myeloma
Significant progress has been made toward the development of effective therapies for multiple myeloma. Current treatment strategies include combinations of several different approved medication classes, including alkylating agents, proteasome inhibitors, immunomodulatory drugs, histone deacetylase inhibitors, and monoclonal antibodies. In this review, we highlight currently active clinical trials for patients with multiple myeloma. Additionally, we describe emerging strategies in the design of future trials, which will include new combinations of available therapies, targeted therapies, immune-based therapies such as chimeric antigen receptors T-cells (CAR-Ts), and drugs with novel mechanisms of action.